medac GmbH
Felix Lindekeit has diverse work experience in different companies. Felix started their career as an Auszubildender im Finanzwesen at Postbank Deutschland from August 2011 to May 2013. After that, they worked as a Junior Projektmanager at claim GmbH from November 2014 to November 2016. Felix then joined medac GmbH, where they started as a Praktikum Strategie in January 2017 and later became a Werkstudent Strategie from April 2017 to August 2018. Felix then held the role of Referent der Geschäftsführung from September 2018 to April 2022. Currently, they are working as the Head of Services at medac GmbH starting from April 2022.
Felix Lindekeit completed their Bachelor of Business Psychology (B.A.) degree in Business Psychology at Hochschule Fresenius from 2013 to 2016. Felix then pursued a Master M.Sc. degree in International Management at the International School of Management, Germany from 2016 to 2018. In 2017, they also participated in the International Business Program at the University of the Sunshine Coast for a short duration. Additionally, Felix obtained a certification in Six Sigma Green Belt from TrainingsManufaktur Dreiklang GmbH & Co. KG in March 2021.
medac GmbH
We are a privately held, medium-sized global pharmaceutical and diagnostics company based in Germany. For more than 50 years we have been committed to high quality products, reliable supply and individual customer services. Today, over 2.000 medac employees worldwide are working together to supply more than 90 countries with our products. Since our foundation we have been specialising in the treatment of oncological, haematological, urological, and autoimmune diseases. Today, we are a leading specialist supplier in oncology and rheumatology. We combine the innovative power of a researching pharmaceutical company with the efficiency of a generics manufacturer and offer both therapeutics and diagnostics. Always putting the needs of patients and healthcare professionals first, we are committed to the refinement of established and the development of new products with additional benefits for patients in specific niche indications with high therapeutic needs.